The conversation around Return on Investment (ROI) for AI in healthcare has never been more...
For years, AI has lingered on the periphery of the pharmaceutical world, a source of promise and potential, but also of skepticism and regulatory hesitation.
That era is ending.
At this NEXT Pharma Sydney, the tone was unmistakable: AI isn’t just accepted, it’s expected. Conversations that once revolved around theoretical possibilities have shifted toward implementation in the real world, from regulatory submissions to drug discovery pipelines. This marks a milestone moment. Pharma, long considered conservative by design, is proving that rigor and innovation aren’t opposites, they’re complementary forces.
As one speaker noted, the readiness of the industry to embed AI “within its existing regulatory frameworks” is nothing short of historic. For a sector built on precision, this newfound agility signals something larger: AI has evolved from a black box into a trusted tool.
The personalisation paradox
“Personalisation” might be pharma’s favorite buzzword and its biggest challenge. Despite enthusiasm, many organisations still struggle to deliver truly tailored communications. Fragmented data, legacy systems and siloed teams make personalisation feel more aspirational than achievable.
Yet, the urgency is clear.
Patients now expect the same level of relevance and responsiveness they experience from consumer brands. Healthcare professionals (HCPs) want timely, context-rich engagement, not generic outreach.
The good news?
The technology to make this possible is finally here. The question is whether the industry can execute. The next few years will determine whether personalisation becomes pharma’s reality or remains its rallying cry.
ROI, real-time and the race for relevance
Amid all the AI excitement, one phrase echoed across discussions: “real-time ROI.” Pharma leaders want visibility, not in quarterly reports, but in live dashboards that show what’s working, where engagement peaks and how budgets can be dynamically re-allocated.
This shift represents more than efficiency; it’s a mindset change. The industry is moving from static planning toward agile performance management.
The approach of maintaining control while enabling fluid, data-driven decision-making is gaining traction. Efficiency, in this new era, isn’t about doing more with less; it’s about making every interaction smarter, faster and more meaningful.
A new confidence in pharma
Perhaps the most striking insight wasn’t technological at all, it was emotional. The industry exuded confidence.
After years of cautious experimentation, pharma is ready to own its digital transformation. AI is no longer seen as a threat to compliance or creativity, it’s an enabler of both.
The conversation has shifted from “if” to “how fast.”
The next chapter of pharma will be written not by those who build the most tools, but by those who use them to make care closer, communicate smarter and humanly innovate.
Want to make patient and HCP personalisation real?
